Phase I Study of B440, an Oral Wilms' Tumor 1 Cancer Vaccine Using a Bifidobacterium Vector, in Patients With Metastatic Urothelial Cancer
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-25-00153 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-07. Verfasst von Hideto Ueki und 12 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Immune checkpoint inhibitors (ICIs) demonstrate limited efficacy in metastatic urothelial cancer (mUC), with most patients eventually developing resistance. B440 is an oral cancer vaccine composed of recombinant Bifidobacterium engineered to express the Wilms' tumor 1 (WT1) tumor-associated antigen, designed to elicit tumor-specific T-cell responses via gut-associated lymphoid tissue. This phase I study evaluated the safety, preliminary efficacy, and immunogenicity of B440 in patients with mUC refractory to standard therapies. METHODS Twelve patients with mUC who had progressed after platinum-based chemotherapy, PD-1/PD-L1 inhibitors, and enfortumab vedotin received oral B440 at either 800 mg (n = 6) or 1,600 mg (n = 6) once daily for five consecutive days per week over 4 weeks. The primary end point was dose-limiting toxicity (DLT). Secondary end points included safety, best overall response, and progression-free survival (PFS). WT1-specific T-cell responses were assessed via interferon-γ enzyme-linked immunospot (ELISPOT) assays. Fecal samples were collected for gut microbiome analysis. RESULTS No DLTs were observed. Treatment-related adverse events were mild (grade 1), with transient IL-6 elevations reported in three patients. The disease control rate was 50%, with six patients achieving stable disease. WT1-specific T-cell responses were detected in six patients, who showed numerically longer PFS than ELISPOT-negative patients (117 v 37 days; nominal P = .030, uncorrected for multiple comparisons). Changes in gut microbiome diversity showed exploratory associations with clinical outcomes. CONCLUSION B440 was safe and well tolerated. WT1-specific immune responses correlated with clinical benefit, supporting further investigation of B440 in combination immunotherapy trials.
Zitieren
APA
Ueki, H., Furukawa, J., Hara, T., Goto, K., Tamura, K., Matsushita, Y., Kakei, Y., Murakami, S., Jimbo, N., Teishima, J., Hinata, N., Miyake, H., & Shirakawa, T. (2026). Phase I Study of B440, an Oral Wilms' Tumor 1 Cancer Vaccine Using a Bifidobacterium Vector, in Patients With Metastatic Urothelial Cancer. JCO Oncology Advances, 3(3). https://doi.org/10.1200/oa-25-00153
Vancouver
Ueki H, Furukawa J, Hara T, Goto K, Tamura K, Matsushita Y, et al. Phase I Study of B440, an Oral Wilms' Tumor 1 Cancer Vaccine Using a Bifidobacterium Vector, in Patients With Metastatic Urothelial Cancer. JCO Oncology Advances. 2026;3(3). doi:10.1200/oa-25-00153
BibTeX
@article{Ueki2026,
author = {Ueki, Hideto and Furukawa, Junya and Hara, Takuto and Goto, Keisuke and Tamura, Keita and Matsushita, Yuto and Kakei, Yasumasa and Murakami, Sae and Jimbo, Naoe and Teishima, Jun and Hinata, Nobuyuki and Miyake, Hideaki and Shirakawa, Toshiro},
title = {Phase I Study of B440, an Oral Wilms' Tumor 1 Cancer Vaccine Using a Bifidobacterium Vector, in Patients With Metastatic Urothelial Cancer},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {3},
doi = {10.1200/oa-25-00153}
}
EUVIMED